Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Myo-inositol (MI) supplementation in women with polycystic ovary syndrome (PCOS) has been evaluated over the last years. Many hormonal and reproductive impairments associated with this disorder seem relieved by the supplement. The objective of the meta-analysis was to assess the effects of MI alone or combined with d-chiro-inositol (DCI) on the endocrine and metabolic abnormalities of women with PCOS. Literature was retrieved from selected databases, MEDLINE, EMBASE, PubMed and Research Gate (up to November 2016). Only randomized controlled trials (RCTs) investigating the effects of MI alone or combined with DCI were reviewed. Nine RCTs involving 247 cases and 249 controls were included. Significant decreases in fasting insulin (SMD = −1.021 µU/mL, 95% CI: −1.791 to −0.251, P = 0.009) and homeostasis model assessment (HOMA) index (SMD = −0.585, 95% CI: −1.145 to −0.025, P = 0.041) were identified after MI supplementation. The trial sequential analysis of insulin meta-analysis illustrates that the cumulative z-curve crossed the monitoring boundary, providing firm evidence of the intervention effect. A slight trend toward a reduction of testosterone concentration by MI with respect to controls was found (SMD = −0.49, 95% CI: −1.072 to 0.092, P = 0.099), whereas androstenedione levels remained unaffected. Throughout a subgroup’s meta-analysis, a significant increase in serum SHBG was observed only in those studies where MI was administered for at least 24 weeks (SMD = 0.425 nmol/L, 95% CI: 0.050–0.801, P = 0.026). These results highlight the beneficial effect of MI in improving the metabolic profile of women with PCOS, concomitantly reducing their hyperandrogenism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“From this observation, it has been speculated that PCOS patients with hyperinsulinemia may have an accelerated MI to DCI epimerization, resulting in an overproduction of DCI and consequently an MI deficiency in the ovary (68, 69).”
RetractedHao (2015) · doi:10.1002/14651858 · Cited by 11,321
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Phosphoinositides in cell regulation and membrane dynamics
Di Paolo, G., & De Camilli, P. (2006) · Nature · doi:10.1038/nature05185 · Cited by 2,790
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“It is also associated with several long-term health consequences, including obesity (18, 19), infertility (20), obstetric complications (21), type 2 diabetes (22, 23, 24), cardiovascular disease (24, 25, 26, 27), psychological distress (28) and ostensibly mood disorders (29, 30).”
Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms030 · Cited by 939
Moher, D. (2009) · Journal of Chinese Integrative Medicine · doi:10.3736/jcim20090918 · Cited by 909
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786 · cited 1×
“Interventions improving insulin sensitivity and reducing circulating insulin, such as metformin, troglitazone and pioglitazone, have been shown to reduce circulating testosterone and increase serum SHBG levels (77, 78, 79).”
Cited by
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“In contrast, several lines of evidence proved myo-Ins efficacy and safety in managing PCOS symptoms and improving outcomes [43], with the most promising clinical results observed in obese, insulin-resistant PCOS women, when combining myo-Ins and D-chiro-”
ResultSelf-citationGriffith, R. J., Alsweiler, J., Moore, A. E., Brown, S., Middleton, P., Shepherd, E., & Crowther, C. A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012394.pub3 · Cited by 149
Xing, C., Zhang, J., Zhao, H., & He, B. (2022) · International Journal of Women's Health · doi:10.2147/ijwh.s344542 · Cited by 118
Inositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Self-citationFacchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
“MI has been shown to improve insulin sensitivity and oocyte quality, to reduce hyperandrogenism and regulate menstrual cycles ovulation and hirsutism [10, 46].”
BackgroundSelf-citationKamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
“[83] also demonstrated slight trend toward testosterone decrease with respect to controls, whereas androstenedione levels remained unchanged.”
MethodFacchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Self-citationAkbari Sene, A., Tabatabaie, A., Nikniaz, H., Alizadeh, A., Sheibani, K., Mortezapour Alisaraie, M., Tabatabaie, M., Ashrafi, M., & Amjadi, F. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05111-1 · Cited by 42
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6276187 · Cited by 38
Mendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1576620 · Cited by 36
“MYO supplements have been observed to improve the metabolic profile and hyperandrogenism of women with PCOS [4,5], in addition to increasing the clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET, probably improving the quality of embryos and reducing the number of unsuitable…”
BackgroundCurrent and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
“Nonetheless, due to the considerable heterogeneity across the RCTs included in the meta-analyses, further confirmatory evidence is still needed [40,42].”
BackgroundMoslehi, N., Zeraattalab-Motlagh, S., Rahimi Sakak, F., Shab-Bidar, S., Tehrani, F. R., & Mirmiran, P. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuac075 · Cited by 28
Plant Foods, Healthy Plant-Based Diets, and Type 2 Diabetes: A Review of the Evidence
del Carmen Fernández-Fígares Jiménez, M. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuad099 · Cited by 20
Jethaliya, H., Gajjar, N., Patel, V., Deshpande, S., & Patel, R. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-00933-y · Cited by 17
The "asthma-polycystic ovary overlap syndrome" and the therapeutic role of myo-inositol
Guarnieri, G., Iervolino, M., Cavallone, S., Unfer, V., & Vianello, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086959 · Cited by 11
Self-citationKhan, R. B., Sarosh, M., & Anwer, S. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2216121 · Cited by 2
Metadata
- Authors
- Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J.
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2017-11
- Volume
- 6
- Issue
- 8
- Pages
- 647-658
- ISSN
- 2049-3614 (ISSN-L)
- OpenAlex
- W2766692637
- Cited by
- 188
- References
- 32
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.